{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:58:18Z","timestamp":1793739498864,"version":"4.6.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Infants with premature birth \u226435 weeks gestational age, chronic lung disease of prematurity and congenital heart disease are at an increased risk for lower respiratory tract infections and hospitalization from respiratory syncytial virus (RSV), which has been shown in randomized trials to be prevented by palivizumab. However, palivizumab effectiveness (PE) has not been studied in a large clinical setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A multicenter study among high-risk US and Canadian children younger than 24 months hospitalized with lower respiratory tract infection and whose nasopharyngeal aspirates were tested for human metapneumovirus (HMPV) and RSV were the subjects of the trial. We conducted a test-negative case\u2013control study in these subjects to determine PE. We used an inverse propensity score weighted (IPSW) multiple logistic regression model to adjust PE.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Palivizumab was used in 434 (51%) of 849 eligible children. RSV was identified in 403 (47%) children. The unadjusted PE was 43% [95% confidence interval (CI), 34%\u201351%)]. After IPSW adjustment, the adjusted PE was 58% (95% CI, 43%\u201369%). Palivizumab prevented intensive care unit admissions (PE, 62%; 95% CI, 35%\u201378%). PE for 29\u201335 weeks gestational age and \u22646 months of chronologic age without chronic lung disease of prematurity or congenital heart disease was 74% (95% CI, 56%\u201385%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Using a test-negative case\u2013control design with RSV molecular detection, palivizumab is shown to prevent RSV hospitalizations and intensive care unit admissions in high-risk infants.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001533","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T05:33:23Z","timestamp":1483680803000},"page":"699-704","source":"Crossref","is-referenced-by-count":79,"title":["Effectiveness of Palivizumab in High-risk Infants and Children"],"prefix":"10.1097","volume":"36","author":[{"given":"Evan J.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis","family":"Carosone-Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Yogev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumi","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A. F.","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20231020","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jama.282.15.1440","article-title":"Bronchiolitis-associated hospitalizations among U.S. children, 1980\u20131995.","volume":"282","author":"Shay","year":"1999","journal-title":"JAMA"},{"key":"R2-20231020","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1056\/NEJMoa0804877","article-title":"The burden of respiratory syncytial virus infection in young children.","volume":"360","author":"Hall","year":"2009","journal-title":"N Engl J Med"},{"key":"R3-20231020","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1067\/mpd.2000.110531","article-title":"Rates of hospitalization for respiratory syncytial virus infection among children in medicaid.","volume":"137","author":"Boyce","year":"2000","journal-title":"J Pediatr"},{"issue":"5 suppl","key":"R4-20231020","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1067\/S0022-3476(03)00509-2","article-title":"Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes.","volume":"143","author":"Horn","year":"2003","journal-title":"J Pediatr"},{"key":"R5-20231020","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/INF.0b013e3182184ae7","article-title":"Epidemiology and prevention of respiratory syncytial virus infections among infants and young children.","volume":"30","author":"Langley","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R6-20231020","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1542\/peds.2013-0303","article-title":"Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.","volume":"132","author":"Hall","year":"2013","journal-title":"Pediatrics"},{"key":"R7-20231020","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1211917","article-title":"Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.","volume":"368","author":"Blanken","year":"2013","journal-title":"N Engl J Med"},{"key":"R8-20231020","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/INF.0b013e3181710990","article-title":"FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.","volume":"27","author":"Figueras-Aloy","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"R9-20231020","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/01.inf.0000137568.71589.bd","article-title":"The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.","volume":"23","author":"Law","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R10-20231020","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/INF.0000000000000219","article-title":"Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.","volume":"33","author":"Ambrose","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20231020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","article-title":"Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.","volume":"102","year":"1998","journal-title":"Pediatrics"},{"key":"R12-20231020","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1067\/S0022-3476(03)00454-2","article-title":"Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.","volume":"143","author":"Feltes","year":"2003","journal-title":"J Pediatr"},{"key":"R13-20231020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1542\/peds.2014-1665","article-title":"Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.","volume":"134","year":"2014","journal-title":"Pediatrics"},{"key":"R14-20231020","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1542\/peds.2009-2345","article-title":"From the American Academy of Pediatrics: policy statements\u2014modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.","volume":"124","year":"2009","journal-title":"Pediatrics"},{"key":"R15-20231020","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/INF.0000000000000808","article-title":"Re-evaluating the new committee on infectious diseases recommendations for palivizumab use in premature infants.","volume":"34","author":"Yogev","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20231020","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1016\/j.vaccine.2013.04.026","article-title":"The case test-negative design for studies of the effectiveness of influenza vaccine.","volume":"31","author":"Foppa","year":"2013","journal-title":"Vaccine"},{"key":"R17-20231020","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/j.vaccine.2013.02.053","article-title":"The test-negative design for estimating influenza vaccine effectiveness.","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"R18-20231020","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/ije\/dym021","article-title":"Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness.","volume":"36","author":"Orenstein","year":"2007","journal-title":"Int J Epidemiol"},{"key":"R19-20231020","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES2013.18.37.20585","article-title":"The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials.","volume":"18","author":"De Serres","year":"2013","journal-title":"Euro Surveill"},{"key":"R20-20231020","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/jpids\/pis069","article-title":"Prevalence and characteristics of human metapneumovirus infection among hospitalized children at high risk for severe lower respiratory tract infection.","volume":"1","author":"Anderson","year":"2012","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R21-20231020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"R22-20231020","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"key":"R25-20231020","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/INF.0000000000000922","article-title":"Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian Registry of Palivizumab.","volume":"34","author":"Chan","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R26-20231020","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jpids\/pit007","article-title":"Adherence to immunoprophylaxis regimens for respiratory syncytial virus infection in insured and Medicaid populations.","volume":"2","author":"Escobar","year":"2013","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R27-20231020","doi-asserted-by":"crossref","first-page":"e20160627","DOI":"10.1542\/peds.2016-0627","article-title":"Observed effectiveness of palivizumab for 29-36-week gestation infants.","volume":"138","author":"Farber","year":"2016","journal-title":"Pediatrics"},{"key":"R28-20231020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13052-015-0203-x","article-title":"Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV).","volume":"41","author":"Bollani","year":"2015","journal-title":"Ital J Pediatr"},{"key":"R29-20231020","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/pch\/20.6.321","article-title":"Preventing hospitalizations for respiratory syncytial virus infection.","volume":"20","author":"Robinson","year":"2015","journal-title":"Paediatr Child Health"},{"key":"R30-20231020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijpam.2015.11.005","article-title":"Guidelines for palivizumab prophylaxis in infants and young children at increased risk for respiratory syncytial virus infection in Saudi Arabia.","volume":"3","author":"Al Aql","year":"2016","journal-title":"Int J Pediatr Adolesc Med"},{"key":"R31-20231020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1055\/s-0036-1584147","article-title":"SENTINEL1: an observational study of respiratory syncytial virus hospitalizations among U.S. infants born at 29 to 35 weeks\u2019 gestational age not receiving immunoprophylaxis.","volume":"34","author":"Anderson","year":"2017","journal-title":"Am J Perinatol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201708000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T04:11:20Z","timestamp":1697775080000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201708000-00001"}},"subtitle":["A Propensity Score Weighted Regression Analysis"],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001533","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}